• Existing partnership will be broadened through joint research and development of new Antibody Drug Conjugates (ADCs) involving up to six targets • Heidelberg Pharma’s pipeline will be expanded with new product candidates • Both parties to contribute their strength and proprietary technologies, including Heidelberg Pharma’s ADC technology
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma AG.